Vaccinia immune globulin (VIG) is made from the pooled blood of individuals who have been inoculated with the smallpox vaccine.
[5][6][7][8] In the late 1940s, Henry Kempe suggested that the solution to the complications of the smallpox vaccine was to provide antibodies in the form of gamma globulin, a medical treatment known as passive immunity.
[14] This type of medicine called an antiserum has been used in many treatments successfully, and some research and clinical trials for its use treating monkeypox has been completed.
[17][18][19][20][21] VIGIV is not commercially available but can be made available through the Strategic National Stockpile (SNS) for the treatment of smallpox vaccine complications in patients with serious clinical manifestations.
[26] These (IgG, IgA, IgM, IgD, and IgE) previously have been researched for use with Modified Vaccinia virus Ankara, more so than VIGIV as a treatment for monkeypox.